206 related articles for article (PubMed ID: 23794315)
21. Selective natural kappa opioid and cannabinoid receptor agonists with a potential role in the treatment of gastrointestinal dysfunction.
Fichna J; Schicho R; Janecka A; Zjawiony JK; Storr M
Drug News Perspect; 2009 Sep; 22(7):383-92. PubMed ID: 19890495
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and Pharmacodynamics of Salvinorin A and
Brito-da-Costa AM; Dias-da-Silva D; Gomes NGM; Dinis-Oliveira RJ; Madureira-Carvalho Á
Pharmaceuticals (Basel); 2021 Feb; 14(2):. PubMed ID: 33546518
[No Abstract] [Full Text] [Related]
23. Psychopharmacology of the hallucinogenic sage Salvia divinorum.
Prisinzano TE
Life Sci; 2005 Dec; 78(5):527-31. PubMed ID: 16213533
[TBL] [Abstract][Full Text] [Related]
24. Quantitative determination of salvinorin A, a natural hallucinogen with abuse liability, in Internet-available Salvia divinorum and endemic species of Salvia in Taiwan.
Lin PX; Li JH; Chen SH; Chang HC; McKetin R
J Food Drug Anal; 2014 Sep; 22(3):370-378. PubMed ID: 28911428
[TBL] [Abstract][Full Text] [Related]
25. Determination of salvinorins and divinatorins in Salvia divinorum leaves by liquid chromatography/multistage mass spectrometry.
Medana C; Massolino C; Pazzi M; Baiocchi C
Rapid Commun Mass Spectrom; 2006; 20(2):131-6. PubMed ID: 16331747
[TBL] [Abstract][Full Text] [Related]
26. Novel use patterns of Salvia divinorum: unobtrusive observation using YouTube™.
Casselman I; Heinrich M
J Ethnopharmacol; 2011 Dec; 138(3):662-7. PubMed ID: 21843613
[TBL] [Abstract][Full Text] [Related]
27. Salvia divinorum: An overview of the usage, misuse, and addiction processes.
Mahendran R; Lim HA; Tan JY; Chua SM; Winslow M
Asia Pac Psychiatry; 2016 Mar; 8(1):23-31. PubMed ID: 26617400
[TBL] [Abstract][Full Text] [Related]
28. Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations.
Chavkin C; Sud S; Jin W; Stewart J; Zjawiony JK; Siebert DJ; Toth BA; Hufeisen SJ; Roth BL
J Pharmacol Exp Ther; 2004 Mar; 308(3):1197-203. PubMed ID: 14718611
[TBL] [Abstract][Full Text] [Related]
29. Analysis of the psychoactive terpenoid salvinorin A content in five Salvia divinorum herbal products.
Wolowich WR; Perkins AM; Cienki JJ
Pharmacotherapy; 2006 Sep; 26(9):1268-72. PubMed ID: 16945049
[TBL] [Abstract][Full Text] [Related]
30. Regulating a novel drug: an evaluation of changes in use of Salvia divinorum in the first year of Florida's ban.
Stogner J; Khey DN; Griffin OH; Miller BL; Boman JH
Int J Drug Policy; 2012 Nov; 23(6):512-21. PubMed ID: 22502947
[TBL] [Abstract][Full Text] [Related]
31. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.
Roth BL; Baner K; Westkaemper R; Siebert D; Rice KC; Steinberg S; Ernsberger P; Rothman RB
Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11934-9. PubMed ID: 12192085
[TBL] [Abstract][Full Text] [Related]
32. The antinociceptive effect of salvinorin A in mice.
John TF; French LG; Erlichman JS
Eur J Pharmacol; 2006 Sep; 545(2-3):129-33. PubMed ID: 16905132
[TBL] [Abstract][Full Text] [Related]
33. Antinociceptive and hypothermic effects of Salvinorin A are abolished in a novel strain of kappa-opioid receptor-1 knockout mice.
Ansonoff MA; Zhang J; Czyzyk T; Rothman RB; Stewart J; Xu H; Zjwiony J; Siebert DJ; Yang F; Roth BL; Pintar JE
J Pharmacol Exp Ther; 2006 Aug; 318(2):641-8. PubMed ID: 16672569
[TBL] [Abstract][Full Text] [Related]
34. The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A reduce inflammation-induced hypermotility in mice.
Capasso R; Borrelli F; Zjawiony J; Kutrzeba L; Aviello G; Sarnelli G; Capasso F; Izzo AA
Neurogastroenterol Motil; 2008 Feb; 20(2):142-8. PubMed ID: 17931335
[TBL] [Abstract][Full Text] [Related]
35. Case series: Salvia divinorum as a potential addictive hallucinogen.
El-Khoury J; Baroud E
Am J Addict; 2018 Apr; 27(3):163-165. PubMed ID: 29596726
[TBL] [Abstract][Full Text] [Related]
36. The Association of Salvia divinorum and Psychotic Disorders: A Review of the Literature and Case Series.
El-Khoury J; Sahakian N
J Psychoactive Drugs; 2015; 47(4):286-92. PubMed ID: 26317561
[TBL] [Abstract][Full Text] [Related]
37. Cytotoxic Effects of Salvinorin A, A Major Constituent of Salvia divinorum.
Martinho A; Silva SM; Gallardo E
Med Chem; 2016; 12(5):432-40. PubMed ID: 26434801
[TBL] [Abstract][Full Text] [Related]
38. Salvinorin A fails to substitute for the discriminative stimulus effects of LSD or ketamine in Sprague-Dawley rats.
Killinger BA; Peet MM; Baker LE
Pharmacol Biochem Behav; 2010 Sep; 96(3):260-5. PubMed ID: 20493209
[TBL] [Abstract][Full Text] [Related]
39. Chemogenomics knowledgebase and systems pharmacology for hallucinogen target identification-Salvinorin A as a case study.
Xu X; Ma S; Feng Z; Hu G; Wang L; Xie XQ
J Mol Graph Model; 2016 Nov; 70():284-295. PubMed ID: 27810775
[TBL] [Abstract][Full Text] [Related]
40. Subjective effects of Salvia divinorum.
Dalgarno P
J Psychoactive Drugs; 2007 Jun; 39(2):143-9. PubMed ID: 17703708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
